清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study

医学 实体瘤疗效评价标准 肝细胞癌 内科学 临床终点 不利影响 胃肠病学 临床研究阶段 进行性疾病 无进展生存期 肿瘤科 外科 临床试验 总体生存率 化疗
作者
Chengsheng Zhang,Zhiming Zeng,Manyun Zhuo,Jingru Luo,Xiaohong Zhuang,Jianming Xu,Jie Zeng,Jie Ma,Haifeng Lin
出处
期刊:Oncologist [AlphaMed Press]
卷期号:28 (12): e1239-e1247 被引量:1
标识
DOI:10.1093/oncolo/oyad169
摘要

For patients with unresectable hepatocellular carcinoma (HCC), the first-line therapeutic options are still relatively limited, and treatment outcomes remain poor. We aimed to assess the efficacy and safety of anlotinib combined with toripalimab as first-line therapy for unresectable HCC.In this single-arm, multicenter, phase II study (ALTER-H-003), patients with advanced HCC without previous systemic anticancer therapy were recruited. Eligible patients were given anlotinib (12 mg on days 1-14) combined with toripalimab (240 mg on day 1) in a 3-week cycle. The primary endpoint was the objective response rate (ORR) by immune-related Response Evaluation Criteria in Solid Tumours (irRECIST)/RECIST v1.1 and modified RECIST (mRECIST). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.Between January 2020 and Jul 2021, 31 eligible patients were treated and included in the full analysis set. At data cutoff (January 10, 2023), the ORR was 29.0% (95% CI: 12.1%-46.0%) by irRECIST/RECIST v1.1, and 32.3% (95% CI: 14.8%-49.7%) by mRECIST criteria, respectively. Confirmed DCR and median DoR by irRECIST/RECIST v1.1 and mRECIST criteria were 77.4 % (95% CI: 61.8%-93.0%) and not reached (range: 3.0-22.5+ months), respectively. Median PFS was 11.0 months (95% CI: 3.4-18.5 months) and median OS was 18.2 months (95% CI: 15.8-20.5 months). Of the 31 patients assessed for adverse events (AEs), the most common grade ≥ 3 treatment-related AEs were hand-foot syndrome (9.7%, 3/31), hypertension (9.7%, 3/31), arthralgia (9.7%, 3/31), abnormal liver function (6.5%, 2/31), and decreased neutrophil counts (6.5%, 2/31).Anlotinib combined with toripalimab showed promising efficacy and manageable safety in Chinese patients with unresectable HCC in the first-line setting. This combination therapy may offer a potential new therapeutic approach for patients with unresectable HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纯情的阁发布了新的文献求助10
2秒前
2秒前
缥缈的鸡翅完成签到,获得积分10
5秒前
科研通AI6.4的应助被纯情的阁采纳,获得10
10秒前
10秒前
故意的冷安完成签到,获得积分10
12秒前
17秒前
坚定的咖啡完成签到,获得积分10
17秒前
冷艳千柳完成签到,获得积分10
17秒前
20秒前
36秒前
36秒前
科研通AI6.4的应助被纯情的阁采纳,获得10
37秒前
科研通AI6.4的应助被纯情的阁采纳,获得30
37秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
37秒前
池雨完成签到 ,获得积分10
52秒前
苗条的香萱完成签到,获得积分10
1分钟前
年轻狗完成签到,获得积分10
1分钟前
1分钟前
1分钟前
研友_nqrKQZ发布了新的文献求助10
1分钟前
隐形曼青的应助被研友_nqrKQZ采纳,获得10
1分钟前
1分钟前
爱听歌的语堂完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
搞怪山河完成签到,获得积分10
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
星辰大海的应助被天熙采纳,获得10
1分钟前
纯情的阁发布了新的文献求助30
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得30
1分钟前
1分钟前
1分钟前
xun发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158905
求助须知:如何正确求助?哪些是违规求助? 9554522
关于积分的说明 21719373
捐赠科研通 7748459
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552006
邀请新用户注册赠送积分活动 2471370